Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis
In patients with a first demyelinating event, DIS in ≥4 regions typically affected in MS is highly specific, indicating an extremely low risk of false-positive results, and misdiagnosis. Using DIS in ≥4 regions would reduce the need for follow-up MRI or CSF examination in all patients with suspected MS, streamlining the diagnostic process. Limitations include an over-representation of patients with optic neuritis at onset, a low rate of CSF examination, and lack of optical coherence tomography data.
Authors
- Ahmed Toosy (ORCID: https://orcid.org/0000-0002-4441-3750)
- Michael A. Foster (ORCID: https://orcid.org/0000-0001-7201-7475)
- Indran Davagnanam (ORCID: https://orcid.org/0000-0002-0363-1911)
- Giuseppe Pontillo (ORCID: https://orcid.org/0000-0001-5425-1890)
- Sara Collorone (ORCID: https://orcid.org/0000-0003-1506-8983)
- Ferrán Prados (ORCID: https://orcid.org/0000-0002-7872-0142)
- Frederik Barkhof (ORCID: https://orcid.org/0000-0003-3543-3706)
- Alan J. Thompson (ORCID: https://orcid.org/0000-0002-4333-8496)
- Olga Ciccarelli (ORCID: https://orcid.org/0000-0001-7485-1367)
- Wallace Brownlee (ORCID: https://orcid.org/0000-0003-0481-8902)
- Baris Kanber (ORCID: https://orcid.org/0000-0003-2443-8800)
Institutions
- Universitat Oberta de Catalunya (ES)
- Multiple Sclerosis Society (GB)
- UCL Biomedical Research Centre (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Amsterdam University Medical Centers (NL)
- University College London (GB)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Neurology
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1212/wnl.0000000000210274
- Citations
- 6
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 8.83
Funders
- Sanofi
- Biogen
- European Committee for Treatment and Research in Multiple Sclerosis
- Prothena
- Celltrion
- National Institute for Health and Care Research
- Rosetrees Trust
- Eisai
- University College London Hospitals NHS Foundation Trust
- IXICO
- MedDay Pharmaceuticals
- Medical Research Council